Next Article in Journal
Sirtuins—The New Important Players in Women’s Gynecological Health
Next Article in Special Issue
Cellular Oxidative Stress
Previous Article in Journal
Involvement of RAGE and Oxidative Stress in Inflammatory and Infectious Skin Diseases
Previous Article in Special Issue
Molecular and Cellular Mechanisms Associated with Effects of Molecular Hydrogen in Cardiovascular and Central Nervous Systems
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antioxidants
Volume 10
Issue 1
10.3390/antiox10010083
antioxidants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Role of Phytochemicals in Perturbation of Redox Homeostasis in Cancer

by
Shreyas Gaikwad
and
Sanjay K. Srivastava
*
Department of Immunotherapeutics and Biotechnology, Center for Tumor Immunology and Targeted Cancer Therapy, Texas Tech University Health Sciences Center, Abilene, TX 79601, USA
*
Author to whom correspondence should be addressed.
Antioxidants 2021, 10(1), 83; https://doi.org/10.3390/antiox10010083
Submission received: 25 November 2020 / Revised: 5 January 2021 / Accepted: 5 January 2021 / Published: 9 January 2021
(This article belongs to the Special Issue Cellular Oxidative Stress)
Browse Figures
Versions Notes

Abstract

:
Over the past few decades, research on reactive oxygen species (ROS) has revealed their critical role in the initiation and progression of cancer by virtue of various transcription factors. At certain threshold values, ROS act as signaling molecules leading to activation of oncogenic pathways. However, if perturbated beyond the threshold values, ROS act in an anti-tumor manner leading to cellular death. ROS mediate cellular death through various programmed cell death (PCD) approaches such as apoptosis, autophagy, ferroptosis, etc. Thus, external stimulation of ROS beyond a threshold is considered a promising therapeutic strategy. Phytochemicals have been widely regarded as favorable therapeutic options in many diseased conditions. Over the past few decades, mechanistic studies on phytochemicals have revealed their effect on ROS homeostasis in cancer. Considering their favorable side effect profile, phytochemicals remain attractive treatment options in cancer. Herein, we review some of the most recent studies performed using phytochemicals and, we further delve into the mechanism of action enacted by individual phytochemicals for PCD in cancer.

1. Introduction

1.1. ROS and Its Physiological Role

Reactive oxygen species (ROS) is a blanket term which encompasses several reactive species derived from molecular oxygen [1]. ROS are short-lived highly reactive byproducts of aerobic metabolism. They are formed due to single-electron reduction of oxygen (O2) which forms radical superoxide (O2•−). The superoxide molecules are then converted to hydrogen peroxide (H2O2) in the presence of superoxide dismutase [2]. Reactions involving H2O2 and O2− result in further generation of other ROS molecules such as hydroxyl radicals (OH), singlet oxygen (1O2), and peroxynitrite (ONOO−) [3]. Mitochondria is the biggest source of ROS where 80% of the ROS are generated. Once generated, ROS oxidize several cellular molecules and hence play diverse roles in various physiological processes of the cells [4]. ROS react with carbohydrates, lipids, proteins, and nucleic acids, resulting in functional alterations of pathways associated with cellular differentiation, proliferation, cytoskeletal regulation, and apoptosis [3,5]. Several protein structures such as ion channels, kinases, phosphatases are regulated by redox signaling [5,6]. In signal transduction, ROS transiently oxidizes the cysteine sulfhydryl group which is involved in the activation of most phosphatases [7]. ROS have been considered as a harmful by-product of aerobic metabolism, however, under balanced conditions, ROS play an important role as mediators of signaling pathways in various physiological systems [8]. The biological activity of ROS depends on the extent, location, and duration of action of the specific ROS molecule [9]. For example, in embryonic development, optimum levels of H2O2 are considered to be crucial for neuronal growth. A level of 1–10 nM H2O2 is required for neuronal growth as levels below 1 nM have shown spatial memory defects in mice studies, while levels above 10 nM result in axonal degeneration [10,11] In the cardiovascular system, mitochondrial ROS (mROS) are suggested to be involved in the dilation of human coronary resistance arteries in response to shear stress [12]. Additionally, in terms of optimal vascular angiogenesis, NADPH oxidase (NOX) is activated by vascular endothelial growth factor (VEGF) to produce ROS. The produced ROS and VEGF together then induce endothelial cell proliferation and migration [13]. For optimal blood vessel growth, a specific range of ROS called the “redox window” is required [14]. ROS have been observed to be involved in cognitive functioning wherein it was determined that mROS potentiates post-synaptic inhibitory signaling in cerebellar stellate cells via selective recruitment of α3-containing GABAA receptors [15]. Host-defense against pathogens was the first function of ROS to be discovered. Hypochlorous acid (HOCl) produced from chlorine and H2O2 generates chloramines which have cytotoxic effects [16]. In terms of host defense mechanism, after phagocytosis of the pathogen, NADPH oxidase (NOX) produces a high amount of ROS which in turn destructs the pathogen [17]. In the immune system, ROS coordinate the migration of polymorphonuclear leukocytes (PMNs) towards the pathogens, and then ROS also retain the PMNs at the site of infection [18]. T cell activation and proliferation are mediated through a signaling cascade mainly involving the MAPK/ERK pathway [19]. Protein tyrosine phosphatases (PTPs) negatively regulate the MAPK/ERK pathway and PTPs have a cysteine (Cys) residue in their active site which is regulated by ROS. ROS act as inhibitor of PTP by converting Cys residue in the active site to sulfenic acid (Cys-SOH), thus leading to activation of the MAPK/ERK pathway [20]. To summarize, ROS serve as important mediators in several physiological systems and the level of ROS molecules play a key role in its action.

1.2. Oxidative Stress in Cancer

A constant balance of ROS levels is required for appropriate homeostasis. Under normal conditions, our body’s antioxidant defense system continuously counteracts the oxidative attack from ROS molecules [21]. However, excessive accumulation of ROS within the cell disrupts the balance, leading to the generation of oxidative stress [22,23]. The generated oxidative stress leads to irreversible damage of DNA, peroxidation of lipids, oxidation of proteins, and inhibition of enzymes [1]. A high level of ROS present in oxidative stress conditions leads to the activation of various oncogenic pathways [6]. The phosphoinositide 3-kinases (PI3K) pathway is highly activated in a number of cancers. ROS primarily inactivate phosphatase and tensin homolog (PTEN) in the PI3K pathway by oxidizing Cys124, an active site on PTEN, leading to a disulfide bond with another intraprotein Cys71. Consequently, the inactivation of PTEN leads to hyper-activation of the PI3K pathway [24]. Constant phosphorylation of PI3K subsequently results in the activation of protein kinase B (AKT) via downstream pyruvate dehydrogenase kinase 1 (PDK1), ultimately leading to the upregulation of cell cycle stimulating genes such as proliferating cell nuclear antigen (PCNA) and cyclin-dependent kinase 1 (CDK1) [25]. In many Kirsten rat sarcoma viral oncogene homolog (KRAS) mutated oncogenic cancers, ROS play an important role in anchorage-independent growth through regulation of the ERK MAPK signaling pathway [26]. In the initial stage of tumor formation, angiogenesis is absent or poorly developed, resulting in hypoxic conditions. The hypoxic condition affects the mitochondrial electron transport chain (ETC), leading to increased ROS levels. Hypoxia-driven ROS play a role in the activation of hypoxia inducing factor-1 (HIF-1), a transcription factor that contributes towards glucose to lactate conversion for tumor glucose metabolism and the induction of VEGF. ROS activate the HIF-1 subunit by inactivating a HIF-1 inhibitor, PHD (prolyl dydroxylase domain) [27]. Increased ROS levels have been linked to tumor proliferation via the c-Myc pathway. At increased ROS levels, HIF-1 α dependent activation of c-Myc occurs, resulting in tumor proliferation and DNA damage [28]. ROS also play a role in tumor stromal environment and activate invasive tumor progression. Increased ROS levels in stromal fibroblasts by transforming growth factor beta-1 (TGFß1) initiated the mesenchymal–mesenchymal transition (MMT) and secretion of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and interleukin-6 which are biomarkers for invasive tumor cells [29]. ROS affect the matrix metalloproteinase (MMP)/tissue inhibitor of metalloproteinase (TIMPs) ratio by activating MMP synthesis. ROS activate MMP synthesis either via Ras and MAPK signaling cascades or through NFκB pathway [30]. Cancer cells survive on levels of ROS that are slightly greater than normal cell counterparts and activate various oncogenic pathways. The cells adapt themselves to the moderate redox environment and proliferate. However, if ROS levels rise beyond a certain threshold, the transformed cancer cells are longer able to adapt and turn to various cell death pathways [31].

2. ROS and Associated Programmed Cell Death (PCD) Pathways

2.1. Apoptosis

Among all the PCD pathways, apoptosis is the most studied pathway which is mediated via a group of proteins called cysteine-dependent aspartate-directed proteases known as caspases [32]. ROS play a role in both extrinsic and intrinsic apoptosis pathways. The intrinsic pathway is mediated through the mitochondrial permeability transition pore (mPTP). ROS cause cytoplasmic release of cytochrome c from the mitochondria via its action on PTP. Specifically, ROS govern the regulation of three proteins adenine nucleotide translocase (ANT), cyclophilin D, and voltage-dependent anion-selective channel (VDAC) involved in the opening of PTP. ROS oxidizes specific cysteines in their active sites [33,34]. The intrinsic pathway is a more common apoptosis mode mediated by ROS since mitochondria is very sensitive to the increased ROS levels as it lacks DNA repair enzymes. In hyperactivated oxidative stress, the shutdown of mitochondrial function contributes to apoptosis as cellular energy supply stops [35,36]. In the extrinsic pathway also known as the death receptor pathway, TNF receptors are involved which are located at the plasma membrane and contain an intracellular death domain. These receptors recruit pro-caspases and adaptor proteins, which results in the formation of death-inducing signaling complex (DISC) and activates the caspases [37]. In this process, the cellular FLICE-inhibitory protein (c-FLIP) impedes the formation of DISC [38]. ROS mediate the downregulation of FLIP by ubiquitination and subsequent degradation by the proteasome. Primarily, H2O2 and O2•− are responsible for FLIP down-regulation [39].

2.2. Autophagy

Autophagy is a catabolic process required for the regeneration of damaged organelles and cellular components under various stressful environments such as pathogen infection, growth factor deprivation, starvation, and intra-cellular stress [40]. Autophagy involves the generation of a double-membrane vesicle, called autophagosome, which engulfs the damaged components and merges with lysosome for hydrolytic degradation of the engulfed cargo [41,42]. A definite interplay exists between ROS and autophagy since both are induced by common oncogenic stimuli [43]. Under normal conditions, autophagy mediates cell survival by eliminating ROS and protecting the mitochondria. However, when stimulated, ROS induce excess autophagy resulting in cell death [44]. ROS regulates a negative regulator of autophagy, the mammalian target of rapamycin complex 1 (mTORC1). Inhibition of mTORC1 is mediated through cytoplasmic ataxia telangiectasia mutated (ATM). ATM activates the tuberous sclerosis complex 2 (TSC2) tumor suppressor which inhibits mTOR via stimulation of GTP hydrolysis of Ras family small GTPase Rheb (Ras homolog enriched in brain) [45,46]. Additionally, oxidative stress activates FOXO3 which stimulates the transcription of Bcl-2 nineteen kilodalton interacting protein (BNIP3) [47]. BNIP3 in turn competes with Beclin-1 for binding to Bcl-2. The unbound Beclin1 induce autophagic cell death [48]. However, autophagy acts in a context dependent manner and might play a pro-tumor role in certain conditions [49].

2.3. Ferroptosis

Ferroptosis, a novel form of programmed cell death, is characterized by the accumulation of iron and lipid peroxidation, leading to intracellular changes such as changes in mitochondrial structure and functioning [50]. The mechanism involved in ferroptosis is the suppression of system Xc, an amino acid antitransporter. System Xc is a part of an important antioxidant system in cells that provokes the synthesis of glutathione (GSH). GSH decreases ROS levels under the action of glutathione peroxidases (GPXs), thereby maintain a balanced oxidant-antioxidant environment. During ferroptosis, inhibiting system Xc causes decreased synthesis of GSH, leading to the accumulation of lipid ROS and ultimately, oxidative cell death [51]. Among GPXs, GPX4 is a pivotal player that counterbalances lipid peroxides and protects membrane integrity by using GSH as a cofactor [52]. In terms of cancer therapy, GPX4 is targeted as it is a specific and central regulator of ferroptotic cell death [53].

2.4. Pyroptosis

Pyroptosis is a caspase-dependent (caspase 1/4/5/11) mode of cell death, which is initiated by the formation of the inflammasome. The mechanism involves caspase-mediated cleavage of gasdermin D (GSDMD) and gasdermin E (GSDME). Following the cleavage, the N-terminal fragment of GSDMD is released and it forms pores in the cell membrane, leading to activation of inactive cytokines like IL-18 and IL-1β, water influx, cell swelling, and osmotic lysis [54]. ROS induce pyroptosis through the activation of NLR family pyrin domain containing 3 (NLRP3) inflammasome [55].

2.5. Anoikis

Anoikis is another apoptotic PCD wherein cells undergo death in the absence or improper attachment to the extracellular matrix (ECM). Anoikis is a Greek term for “homelessness” [56,57,58]. In cancer cells, the sonic hedgehog/Gli1 pathway is a well-known regulator of anoikis [59,60]. Additionally, ROS has been implicated to support anoikis resistance, however, depending upon the activation, ROS trigger anoikis-inducing cell death [61].

3. Phytochemicals: A Promising Role in ROS Mediated Cancer Cell Death

Considering the plethora of evidence generated from various studies, it is clear that beyond a threshold value, ROS play an anti-tumorigenic role. Therapeutic interventions to achieve the required threshold ROS level is a promising strategy for inducing PCD. Phytochemicals are naturally occurring compounds derived from plants and have been studied for their therapeutic effects in various physiological conditions. Multiple phytochemicals have proven their inheritance of cancer prevention and therapeutic properties [62,63]. The low side-effect profile of phytochemicals has made them a prominent arsenal against cancer. These naturally derived compounds are a valuable resource for cancer treatment and we hereupon discuss some of the phytochemicals studied in ROS-mediated anti-cancer activity.

3.1. Phytochemicals Acting via ROS-Mediated Apoptosis

3.1.1. Capsaicin

Capsaicin (N-vanillyl-8-methylnonenamide) is a homovanillic acid derivative obtained from hot chili pepper [64]. Capsaicin has been widely studied for its anti-cancer activity [65,66]. Its activity is proposed to be mediated through oxidative stress-induced apoptosis. In pancreatic cancer cell lines BXPC-3 and AsPC-1, 4 to 6-fold ROS generation was observed within 1 h of capsaicin treatment while ROS generation was absent in normal pancreatic cells. Capsaicin induced oxidation of cardiolipin, a component of mitochondria. Oxidation of cardiolipin subsequently led to apoptosis. ETC complex-I and complex-III were observed to be the ROS-producing entities following capsaicin treatment [67,68].

3.1.2. Sulforaphane

Sulforaphane (SFN; 1-isothiocyanato-4-(methyl-sulfinyl)-butane) is an isothiocyanate present in cruciferous vegetables like cabbage, broccoli, cauliflower, and kale [69]. Sulforaphane induced ROS mediated apoptosis in PC-3 and DU145 human prostate cancer cells. Specifically, caspase-8 activation and Fas protein induction following sulforaphane treatment confirmed apoptotic activity. ROS generation was suggested to be caused by both nonmitochondrial and mitochondrial mechanisms. GSH depletion was proposed to be the non-mitochondrial mechanism. ROS were postulated to be upstream activators of apoptosis based on caspase-8 attenuation following treatment with EUK-134 (SOD and catalase mimetic) [70].

3.1.3. α-Lipoic Acid

α-lipoic acid (1,2-Dithiolan-3-yl pentanoic acid) is a naturally occurring dithiol compound found in fruits and vegetables [71]. In hepatocellular carcinoma cell line HepG2, it induced mitochondrial apoptosis preceded by ROS generation. Precisely, α-lipoic acid-induced ER (endoplasmic reticulum) stress wherein increased levels of C/EBP homologous protein (CHOP) were detected. ER stress led to activation of PERK (phospho- extracellular signal-related kinase) pathway and IRE1 (inositol-requiring enzyme 1) pathway leading to apoptosis. α-lipoic acid also inhibited ATF6 (activating transcription factor 6)-mediated pro-survival pathway [72].

3.1.4. Benzyl Isothiocyanate (BITC)

BITC is an isothiocyanate present in cruciferous vegetables such as cauliflower, mustard, watercress, cabbage, and horseradish [73]. BITC has been studied for its anti-cancer effects in various studies previously [74,75,76,77,78]. BITC was studied for its anti-cancer potential in pancreatic cancer cell lines Capan-2 and MIAPaCa-2 cells. BITC treatment activated MAPK signaling with activation of ERK and JNK observed within as early as 1 h of treatment while ROS generation was observed within 30 min of treatment. Additionally, activation of MAPK family members was absent in normal HPDE-6 cell line. Thus, BITC treatment led to ROS generation followed by activation of MAPK family members ERK, JNK, and P38 and subsequently apoptosis [79].

3.1.5. Phenethyl Isothiocyanate (PEITC)

PEITC, another isothiocyanate present in cruciferous vegetables has been studied for its anti-cancer effects and ROS-generating properties [80,81,82,83,84,85]. In a study to investigate effects of PEITC on breast cancer cells, PEITC showed ROS-mediated apoptosis in MDA-MB-231 and MCF-7 cell lines. High levels of hydrogen peroxide were observed in the cancer cells following treatment with PEITC. An antioxidant pre-treatment blocked cellular death and percent apoptosis induced by PEITC. Thus, confirming high levels of ROS led to apoptotic cell death [86].

3.1.6. Piperine

Piperine [1-(5-[1,3-benzodioxol-5-yl]-1-oxo-2,4-pentadienyl) piperidine] is an alkaloid extracted from black pepper (P. nigrum) and long pepper (P. longum) [87]. Various small molecules derived from the Piperaceae family have been implicated in ROS-mediated apoptotic cell death of cancer cells [88,89]. Piperine has been implicated for ROS generation in SKMEL-28 and B16-F0 melanoma cell lines. ROS generation was observed within 30 min of treatment and the levels sustained until 24 h. Phosphorylation of Chk1 (checkpoint kinase 1) was observed in response to DNA damage which consequently led to G1 cell cycle arrest and apoptosis. Significant expression of phosphorylated ataxia telangiectasia and Rad3 related protein (ATR) at Ser 428 and Chk1 at Ser 296 was observed, suggesting DNA damage [90].

3.1.7. Curcumin

Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a polyphenol derived from rhizome of Curcuma longa. It possesses pleiotropic therapeutic benefits including anti-cancer effects [91,92]. The apoptotic role of curcumin was studied in colorectal cancer and sequential dosing was considered important for ROS-mediated apoptotic induction. In the study, the sequential treatment caused lysosomal permeabilization and ROS generation, accompanied by autophagic dysregulation and ER stress. Lysosomal permeabilization resulted in BID-dependent mitochondrial membrane permeabilization and thereby caspase-dependent apoptosis. Cathepsin B was confirmed to be involved in apoptosis following sequential treatment [93]. Figure 1 depicts the ROS-mediated apoptotic action of phytochemicals.

3.2. Phytochemicals Acting via ROS-Mediated Ferroptosis

3.2.1. Withaferin A

Withaferin A (WA) is a steroidal lactone isolated from the plant Withania somnifera. It has been widely studied for anti-inflammatory and anti-tumorigenic properties [94]. Withaferin A induced ferroptotic cell death in neuroblastoma cells. WA targeted Keap-1 (kelch-like ECH-associated protein (1), a negative regulator of Nrf2 (nuclear factor erythroid 2-related factor (2). Keap-1 inhibition caused the release of Nrf2. The released Nrf2 upregulated HMOX1 [heme oxygenase (decycling) 1] which catalyzes heme degradation to generate ferrous iron (Fe2+). A high concentration of Fe2+ led to ROS generation and ultimately cellular death [95].

3.2.2. Bromelain

Bromelain is a mixture of proteolytic enzymes derived from the stem of pineapple plants belonging to the Bromeliaceae family [96]. Bromelain was shown to induce ferroptotic cell death in KRAS-mutant colorectal cancer wherein bromelain increased the level of long-chain acyl-CoA synthetase-4 (ACSL4) an isozyme which plays role in lipid biosynthesis and fatty acid degradation. Specifically, ACSL4 accumulates oxidized cellular membrane phosphoplipids. ACSL4 mainly acts on phosphatidylethanolamine levels which act as an executioner of ferroptotic cell death [81,97].

3.2.3. Ruscogenin

Ruscogenin [(1β,3β,25R)-Spirost-5-ene-1,3-diol] is a steroidal sapogenin extracted from Ruscus aculeatus plant [98]. Ruscogenin was studied for ferroptotic effects in pancreatic cancer cell lines BxPC-3, SW1990, PANC-1, and AsPC-1. Ruscogenin treatment increased Fe2+ ion concentration by upregulating the expression of transferrin and downregulating the expression of ferroportin. To further confirm the mode of action, cell death by ruscogenin reduced following treatment with iron chelator and cell death increased when ferric ammonium citrate was added. To conclude, ruscogenin regulated iron transport resulted in overproduction of ROS, leading to cell death [99].

3.2.4. Oridonin

Oridonin (Ori) is a tetracyclic diterpenoid obtained from Isodon Rubescens [100]. The ferroptotic effect of Ori was studied in esophageal cancer cell line TE1 and inhibition of the gamma-glutamyl cycle was observed in oridonin treated cells. Precisely, Ori affected GGT1, a key enzyme in the gamma-glutamyl cycle, which is crucial for protecting cells from oxidative stress and maintaining cysteine homeostasis. Additionally, Ori inhibited GSH by a covalently binding with cysteine after entering the TE1 cells. The covalent binding reduces intracellular cysteine levels which is responsible for ferroptosis. A decrease in GPX4 level was also detected after Ori treatment [101,102]. Figure 2 depicts the ROS-mediated ferroptotic action of phytochemicals.

3.3. Phytochemicals Acting via ROS-Mediated Autophagy

3.3.1. Cucurbitacin B

Cucurbitacin B (1,2-Dihydro-alpha-elaterin) is a tetracyclic triterpene compound found in the plants of Cucurbitaceae and other also a variety of other plant families. Some of the sources of cucurbitacin B are Helicteres angustifolia, Licaniaintra petiolaris, Casearia arborea, and Cucumis prophetarum [103]. Cucurbitacin B has been studied for its anticancer effects in human cervical cancer HeLa cells. Cucurbitacin B induced autophagic cell death and was observed to have mediated through mitochondrial ROS production. Treatment of HeLa cells with cucurbitacin-B resulted in accumulation of several lamellar structures having cytosolic autophagic vacuoles. Additionally, the conversion of non-autophagic soluble LC3 (LC3-I) to autophagic LC3 (LC3-II) was detected following treatment with cucurbitacin-B. Pretreatment with antioxidant NAC and Mito-TEMPO (mitochondria-targeting antioxidant) inhibited LC3-II conversion, cell death, and autophagosome formation. Thus, the results indicated that ROS plays an important role in promoting autophagic cell death following cucurbitacin treatment [104]. Another study confirmed cucurbitacin-B induced autophagic cell death via ROS in MCF-7 breast cancer cells. The role of ROS was confirmed by the use of antioxidant pretreatment which reduced protein expression of LC3 II [105].

3.3.2. Silibinin

Silibinin is a flavonoid derived from the milk thistle plant (Silybum marianum). The autophagic activity of silibinin was studied in human fibro-sarcoma HT1080 cells wherein silibinin was shown to activate p53 via the ROS-p38 pathway. Activation of p53 partially mediated autophagic cell death by inhibiting the MEK/ERK1/2 and PI3K/Akt pathway. An increased expression of Beclin1 (autophagosome marker) and conversion of LC3 I to LC3 II was observed following silibinin treatment [106]. Another study indicated that silibinin induces autophagic cell death mediated through mitochondrial dysfunction [107].

3.3.3. Allicin

Allicin (2-propene-1-sulfinothioic acid S-2-propenyl ester) is an organosulfur compound present in garlic initially studied for its anti-bacterial studies [108]. Allicin was shown to induce both autophagy and apoptosis via increased production of ROS in non-small cell lung cancer cell lines A549 (adenocarcinoma) and NCI-H460 (large cell carcinoma). The authors observed a dose-dependent autophagic action of allicin. At low doses, allicin induced autophagy associated with moderate ROS levels, while increased doses resulted in higher ROS production and lysosomal disruption leading to cell death. The lysosomal disruption resulted in intra-cellular hydrolytic enzyme release [109]. Similar autophagic action of allicin was studied in hepatocellular carcinoma cells. Interestingly, allicin caused autophagy induction in p53 normal human liver cancer cells while apoptosis in p53 deficient cell line showing the dependence of its autophagic action on p53 [110].

3.3.4. Carnosol

Carnosol is an ortho-diphenolic diterpene found in Mediterranean herbs rosemary, sage, and oregano [111]. Although it has been studied for its antioxidant activity, some evidence also shows the cytotoxic effects of carnosol via ROS overproduction. ROS production by carnosol is a dose and time-dependent process [112]. Carnosol study in MDA-MB 231 breast cancer cells showed ROS accumulation within 1 h of treatment while LC3II accumulation at 3 h post-treatment, suggesting ROS to be an upstream inducer of autophagy. It was observed that at lower concentration (<25 µM), carnosol-induced ROS-mediated autophagy only, while at higher concentration (>50 µM), ROS induced both autophagy as well as apoptosis. Interestingly, autophagy induction by carnosol was beclin-1 independent [113].

3.3.5. Quercetin

Quercetin is a flavonoid found in fruits such as grapes, red raspberry, apples, and vegetables like broccoli, shallots, tomatoes, onion, and tea [114]. Quercetin has been widely studied for its anti-cancer effects and exerts its effects through multiple pathways. A study of quercetin in osteosarcoma cells revealed it activates autophagic flux via its action on nuclear protein 1 (NUPR1) which is involved in autophagosome formation, cargo degradation, and autophagosome-lysosome fusion. It was observed that quercetin-induced overproduction of ROS led to increased expression and activation of NUPR1. Although a majority of the studies show an inverse relation between NUPR1 and ROS, a direct relation is hypothesized [115,116].

3.3.6. Berberine

Berberine (5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a] quinolizinium) is a quaternary benzylisoquinoline alkaloid derived from stem bark and roots of many plants and mainly the plants belonging to genus Berberis [117]. Recently, berberine was investigated for its anticancer role in the renal cell carcinoma model wherein it was combined with photodynamic therapy (PDT). The fluorescent nature of berberine was a key characteristic of the combinational effect. Berberine was used as a photosensitizer agent because the complementary action of a photosensitizer agent with a laser induces ROS generation, leading to cellular death. Berberine along with PDT showed significantly increased autophagy in comparison to berberine alone, suggesting photoactivation of berberine is required for ROS-mediated autophagy and ultimate cell death [118]. Figure 3 depicts the ROS-mediated autophagic action of phytochemicals.

3.4. Phytochemicals Acting via ROS-Mediated Pyroptosis

Nobiletin

Nobiletin (5,6,7,8,3′,4′-hexamethoxyflavone) is a polymethoxyflavonoid extracted from citrus fruits. Nobiletin has various pharmacological activities such as antimetabolic disorder, anticancer, neuroprotection, anti-inflammation, antioxidation, and cardiovascular protection [119]. Nobiletin was studied for its anti-cancer activity in human ovarian carcinoma cell lines A2780 and OVCAR3. In the study, nobiletin treatment resulted in ROS generation, exhibited by a significant decrease in mitochondrial membrane potential in a dose-dependent manner. Further, ROS contributed to the cleavage of GSDMD and GSDME, the two biomarkers of pyroptosis among which GSDMD is considered to be an executioner of pyroptosis [120,121]. Figure 4 depicts the ROS-mediated pyroptotic action of phytochemicals.

3.5. Phytochemicals Acting via ROS-Mediated Anoikis

Emodin

Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is an anthraquinone derivative obtained from rhubarb plant (Rheum palmatum) and Aloe vera [122]. Emodin was shown to induce ROS generation followed by anoikis in gastric cancer cells. Emodin induced oxidative stress and caused inactivation of RhoA, a crucial signaling molecule in the cytoskeletal rearrangement. Inactivation of RhoA led to the disruption of focal adhesion complex and ultimately anoikis [61]. Figure 5 depicts the ROS-mediated anoikis by phytochemicals.

4. Conclusions

The ability of natural phytochemicals to modulate various signaling pathways make them promising therapeutic candidates in cancer. Many phytochemicals have progressed towards clinical trials against various malignancies such as breast, pancreatic, colon, and prostate cancers where promising results have been observed. Since cancer cells survive on levels of ROS that are slightly higher than normal cells, they are more sensitive to external perturbation. Fine-tuning of ROS levels using phytochemicals is a promising therapeutic strategy in cancer. Additionally, recent findings such as photooxidative stress using phytochemicals have provided selective targeting of cancer cells. However, there are a few challenges which need to be addressed in terms of the pharmacokinetic parameters of phytochemicals. In order to induce sufficient ROS levels for anti-cancer activity, specific plasma levels of the phytochemicals need to be attained. It has been observed that some of the phytochemicals do achieve the required plasma levels. A few such candidates having good pharmacokinetic parameters include BITC, PEITC, silibinin, and berberine. However, the majority of the phytochemicals fail to achieve required cytotoxic levels. This issue can be addressed by formulating the natural compound in advanced drug delivery systems such as nano drug delivery formulations. Various studies have been conducted in this aspect and nano drug delivery has proven to be an effective tool to achieve high plasma concentrations of the phytochemicals. Some of the successful candidates include sulforaphane and curcumin. A nano structured lipid formulation increased the bioavalability of sulforaphane in rat plasma while a nanoparticle formulation increased curcumin levels in human plasma by 10–15-fold. In the future, large cohort studies of ROS targeted phytochemicals are required, since these studies will provide data regarding efficacy, toxicity, bioavailability in clinical setup for their establishment as anti-cancer therapies in the market. An outline of pharmacokinetic data, selective action between normal and cancer cells by phytochemicals has been presented in Table 1.

Author Contributions

Conception and design of the review, S.G.; writing—original and draft preparation, S.G.; editing, suggestions and supervision S.K.S. All authors have read and agreed to the published version of the manuscript.

Funding

Authors appreciate the financial support from Dodge Jones Foundation, Abilene, Texas.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sies, H.; Jones, D.P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat. Rev. Mol. Cell. Biol. 2020, 21, 363–383. [Google Scholar] [CrossRef] [PubMed]
  2. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87, 315–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Patel, L.R.; Peng, J.; Chilian, W.M. Reactive Oxygen Species: The Good and the Bad. In Reactive Oxygen Species (ROS) in Living Cells; IntechOpen: London, UK, 2017. [Google Scholar] [CrossRef] [Green Version]
  4. Milkovic, L.; Cipak Gasparovic, A.; Cindric, M.; Mouthuy, P.A.; Zarkovic, N. Short Overview of ROS as Cell Function Regulators and Their Implications in Therapy Concepts. Cells 2019, 8, 793. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Winterbourn, C.C. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 2008, 4, 278–286. [Google Scholar] [CrossRef] [PubMed]
  6. Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 2014, 24, R453–R462. [Google Scholar] [CrossRef] [Green Version]
  7. Miki, H.; Funato, Y. Regulation of intracellular signalling through cysteine oxidation by reactive oxygen species. J. Biochem. 2012, 151, 255–261. [Google Scholar] [CrossRef] [Green Version]
  8. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82, 47–95. [Google Scholar] [CrossRef]
  9. Brieger, K.; Schiavone, S.; Miller, F.J., Jr.; Krause, K.H. Reactive oxygen species: From health to disease. Swiss Med. Wkly. 2012, 142, w13659. [Google Scholar] [CrossRef]
  10. Oswald, M.C.W.; Garnham, N.; Sweeney, S.T.; Landgraf, M. Regulation of neuronal development and function by ROS. FEBS Lett. 2018, 592, 679–691. [Google Scholar] [CrossRef]
  11. Wilson, C.; Gonzalez-Billault, C. Regulation of cytoskeletal dynamics by redox signaling and oxidative stress: Implications for neuronal development and trafficking. Front. Cell. Neurosci. 2015, 9, 381. [Google Scholar] [CrossRef] [Green Version]
  12. Liu, Y.; Zhao, H.; Li, H.; Kalyanaraman, B.; Nicolosi, A.C.; Gutterman, D.D. Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ. Res. 2003, 93, 573–580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Ushio-Fukai, M.; Alexander, R.W. Reactive oxygen species as mediators of angiogenesis signaling: Role of NAD(P)H oxidase. Mol. Cell. Biochem. 2004, 264, 85–97. [Google Scholar] [CrossRef] [PubMed]
  14. Yun, J.; Rocic, P.; Pung, Y.F.; Belmadani, S.; Carrao, A.C.; Ohanyan, V.; Chilian, W.M. Redox-dependent mechanisms in coronary collateral growth: The “redox window” hypothesis. Antioxid. Redox Signal. 2009, 11, 1961–1974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Accardi, M.V.; Daniels, B.A.; Brown, P.M.; Fritschy, J.M.; Tyagarajan, S.K.; Bowie, D. Mitochondrial reactive oxygen species regulate the strength of inhibitory GABA-mediated synaptic transmission. Nat. Commun. 2014, 5, 3168. [Google Scholar] [CrossRef] [PubMed]
  16. Fang, F.C. Antimicrobial actions of reactive oxygen species. mBio 2011, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Dupre-Crochet, S.; Erard, M.; Nubetae, O. ROS production in phagocytes: Why, when, and where? J. Leukoc. Biol. 2013, 94, 657–670. [Google Scholar] [CrossRef]
  18. Kuiper, J.W.; Sun, C.; Magalhaes, M.A.; Glogauer, M. Rac regulates PtdInsP(3) signaling and the chemotactic compass through a redox-mediated feedback loop. Blood 2011, 118, 6164–6171. [Google Scholar] [CrossRef] [Green Version]
  19. Tavassolifar, M.J.; Vodjgani, M.; Salehi, Z.; Izad, M. The Influence of Reactive Oxygen Species in the Immune System and Pathogenesis of Multiple Sclerosis. Autoimmune Dis. 2020, 2020, 5793817. [Google Scholar] [CrossRef]
  20. Lee, K.; Esselman, W.J. cAMP potentiates H(2)O(2)-induced ERK1/2 phosphorylation without the requirement for MEK1/2 phosphorylation. Cell. Signal. 2001, 13, 645–652. [Google Scholar] [CrossRef]
  21. Burton, G.J.; Jauniaux, E. Oxidative stress. Best Pr. Res. Clin. Obs. Gynaecol. 2011, 25, 287–299. [Google Scholar] [CrossRef] [Green Version]
  22. Birben, E.; Sahiner, U.M.; Sackesen, C.; Erzurum, S.; Kalayci, O. Oxidative stress and antioxidant defense. World Allergy Organ. J. 2012, 5, 9–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Zuo, L.; Zhou, T.; Pannell, B.K.; Ziegler, A.C.; Best, T.M. Biological and physiological role of reactive oxygen species—The good, the bad and the ugly. Acta Physiol. 2015, 214, 329–348. [Google Scholar] [CrossRef] [PubMed]
  24. Leslie, N.R.; Bennett, D.; Lindsay, Y.E.; Stewart, H.; Gray, A.; Downes, C.P. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003, 22, 5501–5510. [Google Scholar] [CrossRef] [PubMed]
  25. Okoh, V.O.; Felty, Q.; Parkash, J.; Poppiti, R.; Roy, D. Reactive oxygen species via redox signaling to PI3K/AKT pathway contribute to the malignant growth of 4-hydroxy estradiol-transformed mammary epithelial cells. PLoS ONE 2013, 8, e54206. [Google Scholar] [CrossRef]
  26. Weinberg, F.; Hamanaka, R.; Wheaton, W.W.; Weinberg, S.; Joseph, J.; Lopez, M.; Kalyanaraman, B.; Mutlu, G.M.; Budinger, G.R.; Chandel, N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 2010, 107, 8788–8793. [Google Scholar] [CrossRef] [Green Version]
  27. Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004, 4, 891–899. [Google Scholar] [CrossRef]
  28. Vafa, O.; Wade, M.; Kern, S.; Beeche, M.; Pandita, T.K.; Hampton, G.M.; Wahl, G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell 2002, 9, 1031–1044. [Google Scholar] [CrossRef]
  29. Cat, B.; Stuhlmann, D.; Steinbrenner, H.; Alili, L.; Holtkotter, O.; Sies, H.; Brenneisen, P. Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. J. Cell Sci. 2006, 119, 2727–2738. [Google Scholar] [CrossRef] [Green Version]
  30. Kar, S.; Subbaram, S.; Carrico, P.M.; Melendez, J.A. Redox-control of matrix metalloproteinase-1: A critical link between free radicals, matrix remodeling and degenerative disease. Respir. Physiol. Neurobiol. 2010, 174, 299–306. [Google Scholar] [CrossRef] [Green Version]
  31. Ozben, T. Oxidative stress and apoptosis: Impact on cancer therapy. J. Pharm. Sci. 2007, 96, 2181–2196. [Google Scholar] [CrossRef]
  32. Kim, B.; Srivastava, S.K.; Kim, S.H. Caspase-9 as a therapeutic target for treating cancer. Expert Opin. Ther. Targets 2015, 19, 113–127. [Google Scholar] [CrossRef] [PubMed]
  33. Madesh, M.; Hajnoczky, G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J. Cell Biol. 2001, 155, 1003–1015. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Circu, M.L.; Aw, T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 2010, 48, 749–762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Ott, M.; Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria, oxidative stress and cell death. Apoptosis 2007, 12, 913–922. [Google Scholar] [CrossRef] [PubMed]
  36. Wang, J.; Yi, J. Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biol. Ther. 2008, 7, 1875–1884. [Google Scholar] [CrossRef]
  37. Kumar, R.; Herbert, P.E.; Warrens, A.N. An introduction to death receptors in apoptosis. Int. J. Surg. 2005, 3, 268–277. [Google Scholar] [CrossRef] [Green Version]
  38. Safa, A.R.; Day, T.W.; Wu, C.H. Cellular FLICE-like inhibitory protein (C-FLIP): A novel target for cancer therapy. Curr. Cancer Drug Targets 2008, 8, 37–46. [Google Scholar] [CrossRef] [Green Version]
  39. Wang, L.; Azad, N.; Kongkaneramit, L.; Chen, F.; Lu, Y.; Jiang, B.H.; Rojanasakul, Y. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J. Immunol. 2008, 180, 3072–3080. [Google Scholar] [CrossRef] [Green Version]
  40. He, C.; Klionsky, D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43, 67–93. [Google Scholar] [CrossRef] [Green Version]
  41. Xie, Z.; Klionsky, D.J. Autophagosome formation: Core machinery and adaptations. Nat. Cell. Biol 2007, 9, 1102–1109. [Google Scholar] [CrossRef]
  42. Ranjan, A.; Kaushik, I.; Srivastava, S.K. Pimozide Suppresses the Growth of Brain Tumors by Targeting STAT3-Mediated Autophagy. Cells 2020, 9, 2141. [Google Scholar] [CrossRef] [PubMed]
  43. Cordani, M.; Donadelli, M.; Strippoli, R.; Bazhin, A.V.; Sanchez-Alvarez, M. Interplay between ROS and Autophagy in Cancer and Aging: From Molecular Mechanisms to Novel Therapeutic Approaches. Oxid. Med. Cell. Longev. 2019, 2019, 8794612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Chen, Y.F.; Liu, H.; Luo, X.J.; Zhao, Z.; Zou, Z.Y.; Li, J.; Lin, X.J.; Liang, Y. The roles of reactive oxygen species (ROS) and autophagy in the survival and death of leukemia cells. Crit. Rev. Oncol. Hematol. 2017, 112, 21–30. [Google Scholar] [CrossRef] [PubMed]
  45. Li, Y.; Corradetti, M.N.; Inoki, K.; Guan, K.L. TSC2: Filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 2004, 29, 32–38. [Google Scholar] [CrossRef] [PubMed]
  46. Alexander, A.; Kim, J.; Walker, C.L. ATM engages the TSC2/mTORC1 signaling node to regulate autophagy. Autophagy 2010, 6, 672–673. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Dobrowolny, G.; Aucello, M.; Rizzuto, E.; Beccafico, S.; Mammucari, C.; Boncompagni, S.; Belia, S.; Wannenes, F.; Nicoletti, C.; Del Prete, Z.; et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 2008, 8, 425–436. [Google Scholar] [CrossRef]
  48. Burton, T.R.; Gibson, S.B. The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ. 2009, 16, 515–523. [Google Scholar] [CrossRef] [Green Version]
  49. White, E.; DiPaola, R.S. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res. 2009, 15, 5308–5316. [Google Scholar] [CrossRef] [Green Version]
  50. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012, 149, 1060–1072. [Google Scholar] [CrossRef] [Green Version]
  51. Li, J.; Cao, F.; Yin, H.L.; Huang, Z.J.; Lin, Z.T.; Mao, N.; Sun, B.; Wang, G. Ferroptosis: Past, present and future. Cell Death Dis. 2020, 11, 1–13. [Google Scholar] [CrossRef]
  52. Ribas, V.; Garcia-Ruiz, C.; Fernandez-Checa, J.C. Glutathione and mitochondria. Front. Pharm. 2014, 5, 151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Yang, W.S.; SriRamaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.; Clemons, P.A.; Shamji, A.F.; Clish, C.B.; et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014, 156, 317–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Fang, Y.; Tian, S.; Pan, Y.; Li, W.; Wang, Q.; Tang, Y.; Yu, T.; Wu, X.; Shi, Y.; Ma, P.; et al. Pyroptosis: A new frontier in cancer. Biomed. Pharm. 2020, 121, 109595. [Google Scholar] [CrossRef] [PubMed]
  55. Yang, Y.; Liu, P.Y.; Bao, W.; Chen, S.J.; Wu, F.S.; Zhu, P.Y. Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway. BMC Cancer 2020, 20, 28. [Google Scholar] [CrossRef] [PubMed]
  56. Gilmore, A.P. Anoikis. Cell Death Differ. 2005, 12 (Suppl. 2), 1473–1477. [Google Scholar] [CrossRef]
  57. Fofaria, N.M.; Srivastava, S.K. Critical role of STAT3 in melanoma metastasis through anoikis resistance. Oncotarget 2014, 5, 7051–7064. [Google Scholar] [CrossRef] [Green Version]
  58. Fofaria, N.M.; Srivastava, S.K. STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells. Carcinogenesis 2015, 36, 142–150. [Google Scholar] [CrossRef] [Green Version]
  59. Kandala, P.K.; Srivastava, S.K. Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. J. Biol. Chem. 2012, 287, 28745–28754. [Google Scholar] [CrossRef] [Green Version]
  60. Gupta, P.; Gupta, N.; Fofaria, N.M.; Ranjan, A.; Srivastava, S.K. HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells. Cancer Lett. 2019, 442, 68–81. [Google Scholar] [CrossRef]
  61. Cai, J.; Niu, X.; Chen, Y.; Hu, Q.; Shi, G.; Wu, H.; Wang, J.; Yi, J. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia 2008, 10, 41–51. [Google Scholar] [CrossRef] [Green Version]
  62. Ranjan, A.; Ramachandran, S.; Gupta, N.; Kaushik, I.; Wright, S.; Srivastava, S.; Das, H.; Srivastava, S.; Prasad, S.; Srivastava, S.K. Role of Phytochemicals in Cancer Prevention. Int. J. Mol. Sci. 2019, 20, 4981. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Boreddy, S.R.; Srivastava, S.K. Pancreatic cancer chemoprevention by phytochemicals. Cancer Lett. 2013, 334, 86–94. [Google Scholar] [CrossRef] [PubMed]
  64. Cordell, G.A.; Araujo, O.E. Capsaicin: Identification, nomenclature, and pharmacotherapy. Ann. Pharm. 1993, 27, 330–336. [Google Scholar] [CrossRef] [PubMed]
  65. Pramanik, K.C.; Fofaria, N.M.; Gupta, P.; Ranjan, A.; Kim, S.H.; Srivastava, S.K. Inhibition of beta-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear beta-catenin/TCF-1 complex: Critical role of STAT-3. Oncotarget 2015, 6, 11561–11574. [Google Scholar] [CrossRef] [Green Version]
  66. Pramanik, K.C.; Fofaria, N.M.; Gupta, P.; Srivastava, S.K. CBP-mediated FOXO-1 acetylation inhibits pancreatic tumor growth by targeting SirT. Mol. Cancer Ther. 2014, 13, 687–698. [Google Scholar] [CrossRef] [Green Version]
  67. Pramanik, K.C.; Boreddy, S.R.; Srivastava, S.K. Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells. PLoS ONE 2011, 6, e20151. [Google Scholar] [CrossRef] [Green Version]
  68. Zhang, R.; Humphreys, I.; Sahu, R.P.; Shi, Y.; Srivastava, S.K. In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis 2008, 13, 1465–1478. [Google Scholar] [CrossRef] [PubMed]
  69. Houghton, C.A.; Fassett, R.G.; Coombes, J.S. Sulforaphane: Translational research from laboratory bench to clinic. Nutr. Rev. 2013, 71, 709–726. [Google Scholar] [CrossRef]
  70. Singh, S.V.; Srivastava, S.K.; Choi, S.; Lew, K.L.; Antosiewicz, J.; Xiao, D.; Zeng, Y.; Watkins, S.C.; Johnson, C.S.; Trump, D.L.; et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J. Biol. Chem. 2005, 280, 19911–19924. [Google Scholar] [CrossRef] [Green Version]
  71. Shay, K.P.; Moreau, R.F.; Smith, E.J.; Smith, A.R.; Hagen, T.M. Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta 2009, 1790, 1149–1160. [Google Scholar] [CrossRef] [Green Version]
  72. Pibiri, M.; Sulas, P.; Camboni, T.; Leoni, V.P.; Simbula, G. alpha-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells. Sci. Rep. 2020, 10, 7139. [Google Scholar] [CrossRef] [PubMed]
  73. Pramanik, K.C.; Srivastava, S.K.; Boreddy, S.R. Molecular Targets of Benzyl Isothiocyanates in Pancreatic Cancer; IntechOpen: London, UK, 2012. [Google Scholar]
  74. Boreddy, S.R.; Pramanik, K.C.; Srivastava, S.K. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin. Cancer Res. 2011, 17, 1784–1795. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Boreddy, S.R.; Sahu, R.P.; Srivastava, S.K. Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-alpha/VEGF/Rho-GTPases: Pivotal role of STAT-3. PLoS ONE 2011, 6, e25799. [Google Scholar] [CrossRef] [PubMed]
  76. Batra, S.; Sahu, R.P.; Kandala, P.K.; Srivastava, S.K. Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol. Cancer Ther. 2010, 9, 1596–1608. [Google Scholar] [CrossRef] [Green Version]
  77. Sahu, R.P.; Epperly, M.W.; Srivastava, S.K. Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation therapy. Front. Biosci. 2009, 1, 568–576. [Google Scholar] [CrossRef] [Green Version]
  78. Wicker, C.A.; Sahu, R.P.; Kulkarni-Datar, K.; Srivastava, S.K.; Brown, T.L. BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis. Cancer Growth Metastasis 2010, 2009, 45–55. [Google Scholar] [CrossRef] [Green Version]
  79. Sahu, R.P.; Zhang, R.; Batra, S.; Shi, Y.; Srivastava, S.K. Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis 2009, 30, 1744–1753. [Google Scholar] [CrossRef] [Green Version]
  80. Loganathan, S.; Kandala, P.K.; Gupta, P.; Srivastava, S.K. Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. PLoS ONE 2012, 7, e43577. [Google Scholar] [CrossRef] [Green Version]
  81. Park, S.; Oh, J.; Kim, M.; Jin, E.J. Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis. Anim. Cells Syst. 2018, 22, 334–340. [Google Scholar] [CrossRef] [Green Version]
  82. Gupta, P.; Wright, S.E.; Srivastava, S.K. PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth. Oncoimmunology 2015, 4, e981449. [Google Scholar] [CrossRef] [Green Version]
  83. Gupta, P.; Kim, B.; Kim, S.H.; Srivastava, S.K. Molecular targets of isothiocyanates in cancer: Recent advances. Mol. Nutr. Food Res. 2014, 58, 1685–1707. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Gupta, P.; Wright, S.E.; Kim, S.H.; Srivastava, S.K. Phenethyl isothiocyanate: A comprehensive review of anti-cancer mechanisms. Biochim. Biophys. Acta 2014, 1846, 405–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Gupta, P.; Adkins, C.; Lockman, P.; Srivastava, S.K. Metastasis of Breast Tumor Cells to Brain Is Suppressed by Phenethyl Isothiocyanate in a Novel In Vivo Metastasis Model. PLoS ONE 2013, 8, e67278. [Google Scholar] [CrossRef] [PubMed]
  86. Gupta, P.; Srivastava, S.K. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med. 2012, 10, 80. [Google Scholar] [CrossRef] [Green Version]
  87. Gorgani, L.; Mohammadi, M.; Najafpour, G.D.; Nikzad, M. Piperine—The Bioactive Compound of Black Pepper: From Isolation to Medicinal Formulations. Compr. Rev. Food Sci. Food 2017, 16, 124–140. [Google Scholar] [CrossRef] [PubMed]
  88. Dhillon, H.; Chikara, S.; Reindl, K.M. Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Toxicol. Rep. 2014, 1, 309–318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Fofaria, N.M.; Qhattal, H.S.; Liu, X.; Srivastava, S.K. Nanoemulsion formulations for anti-cancer agent piplartine—Characterization, toxicological, pharmacokinetics and efficacy studies. Int. J. Pharm. 2016, 498, 12–22. [Google Scholar] [CrossRef] [Green Version]
  90. Fofaria, N.M.; Kim, S.H.; Srivastava, S.K. Piperine causes G1 phase cell cycle arrest and apoptosis in melanoma cells through checkpoint kinase-1 activation. PLoS ONE 2014, 9, e94298. [Google Scholar] [CrossRef]
  91. Hewlings, S.J.; Kalman, D.S. Curcumin: A Review of Its Effects on Human Health. Foods 2017, 6, 92. [Google Scholar] [CrossRef]
  92. Sahu, R.P.; Batra, S.; Srivastava, S.K. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br. J. Cancer 2009, 100, 1425–1433. [Google Scholar] [CrossRef] [Green Version]
  93. Khaket, T.P.; Singh, M.P.; Khan, I.; Kang, S.C. In vitro and in vivo studies on potentiation of curcumin-induced lysosomal-dependent apoptosis upon silencing of cathepsin C in colorectal cancer cells. Pharm. Res. 2020, 161, 105156. [Google Scholar] [CrossRef] [PubMed]
  94. Vanden Berghe, W.; Sabbe, L.; Kaileh, M.; Haegeman, G.; Heyninck, K. Molecular insight in the multifunctional activities of Withaferin, A. Biochem. Pharm. 2012, 84, 1282–1291. [Google Scholar] [CrossRef] [PubMed]
  95. Hassannia, B.; Wiernicki, B.; Ingold, I.; Qu, F.; Van Herck, S.; Tyurina, Y.Y.; Bayir, H.; Abhari, B.A.; Angeli, J.P.F.; Choi, S.M.; et al. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J. Clin. Investig. 2018, 128, 3341–3355. [Google Scholar] [CrossRef] [PubMed]
  96. Pavan, R.; Jain, S.; Shraddha; Kumar, A. Properties and therapeutic application of bromelain: A review. Biotechnol. Res. Int. 2012, 2012, 976203. [Google Scholar] [CrossRef] [Green Version]
  97. Doll, S.; Proneth, B.; Tyurina, Y.Y.; Panzilius, E.; Kobayashi, S.; Ingold, I.; Irmler, M.; Beckers, J.; Aichler, M.; Walch, A.; et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 2017, 13, 91–98. [Google Scholar] [CrossRef] [PubMed]
  98. Masullo, M.; Pizza, C.; Piacente, S. Ruscus Genus: A Rich Source of Bioactive Steroidal Saponins. Planta Med. 2016, 82, 1513–1524. [Google Scholar] [CrossRef] [Green Version]
  99. Song, Z.; Xiang, X.; Li, J.; Deng, J.; Fang, Z.; Zhang, L.; Xiong, J. Ruscogenin induces ferroptosis in pancreatic cancer cells. Oncol. Rep. 2020, 43, 516–524. [Google Scholar] [CrossRef] [Green Version]
  100. Owona, B.A.; Schluesener, H.J. Molecular Insight in the Multifunctional Effects of Oridonin. Drugs R D 2015, 15, 233–244. [Google Scholar] [CrossRef] [Green Version]
  101. Zhang, J.; Wang, N.; Zhou, Y.; Wang, K.; Sun, Y.; Yan, H.; Han, W.; Wang, X.; Wei, B.; Ke, Y.; et al. Oridonin induces ferroptosis by inhibiting gamma-glutamyl cycle in TE1 cells. Phytother. Res. 2020. [Google Scholar] [CrossRef]
  102. Fujii, J.; Homma, T.; Kobayashi, S. Ferroptosis caused by cysteine insufficiency and oxidative insult. Free Radic. Res. 2019, 10, 1–12. [Google Scholar] [CrossRef]
  103. Garg, S.; Kaul, S.C.; Wadhwa, R. Cucurbitacin B and cancer intervention: Chemistry, biology and mechanisms (Review). Int. J. Oncol. 2018, 52, 19–37. [Google Scholar] [CrossRef]
  104. Zhang, T.; Li, Y.; Park, K.A.; Byun, H.S.; Won, M.; Jeon, J.; Lee, Y.; Seok, J.H.; Choi, S.W.; Lee, S.H.; et al. Cucurbitacin induces autophagy through mitochondrial ROS production which counteracts to limit caspase-dependent apoptosis. Autophagy 2012, 8, 559–576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Ren, G.; Sha, T.; Guo, J.; Li, W.; Lu, J.; Chen, X. Cucurbitacin B induces DNA damage and autophagy mediated by reactive oxygen species (ROS) in MCF-7 breast cancer cells. J. Nat. Med. 2015, 69, 522–530. [Google Scholar] [CrossRef] [PubMed]
  106. Duan, W.J.; Li, Q.S.; Xia, M.Y.; Tashiro, S.; Onodera, S.; Ikejima, T. Silibinin activated p53 and induced autophagic death in human fibrosarcoma HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathways. Biol. Pharm. Bull. 2011, 34, 47–53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  107. Jiang, K.; Wang, W.; Jin, X.; Wang, Z.; Ji, Z.; Meng, G. Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells. Oncol Rep 2015, 33, 2711–2718. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  108. Lawson, L.D.; Hunsaker, S.M. Allicin Bioavailability and Bioequivalence from Garlic Supplements and Garlic Foods. Nutrients 2018, 10, 812. [Google Scholar] [CrossRef] [Green Version]
  109. Pandey, N.; Tyagi, G.; Kaur, P.; Pradhan, S.; Rajam, M.V.; Srivastava, T. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors. Cell Physiol. Biochem. 2020, 54, 748–766. [Google Scholar] [CrossRef]
  110. Chu, Y.L.; Ho, C.T.; Chung, J.G.; Raghu, R.; Lo, Y.C.; Sheen, L.Y. Allicin induces anti-human liver cancer cells through the p53 gene modulating apoptosis and autophagy. J. Agric. Food Chem. 2013, 61, 9839–9848. [Google Scholar] [CrossRef]
  111. Johnson, J.J. Carnosol: A promising anti-cancer and anti-inflammatory agent. Cancer Lett. 2011, 305, 1–7. [Google Scholar] [CrossRef] [Green Version]
  112. Choi, S.M.; Kim, D.H.; Chun, K.S. Carnosol induces apoptotic cell death through ROS-dependent inactivation of STAT3 in human melanoma G361 cells. Appl. Biol. Chem. 2019, 62, 1–11. [Google Scholar] [CrossRef]
  113. Al Dhaheri, Y.; Attoub, S.; Ramadan, G.; Arafat, K.; Bajbouj, K.; Karuvantevida, N.; AbuQamar, S.; Eid, A.; Iratni, R. Carnosol induces ROS-mediated beclin1-independent autophagy and apoptosis in triple negative breast cancer. PLoS ONE 2014, 9, e109630. [Google Scholar] [CrossRef]
  114. Mlcek, J.; Jurikova, T.; Skrovankova, S.; Sochor, J. Quercetin and Its Anti-Allergic Immune Response. Molecules 2016, 21, 623. [Google Scholar] [CrossRef] [PubMed]
  115. Hamidi, T.; Cano, C.E.; Grasso, D.; Garcia, M.N.; Sandi, M.J.; Calvo, E.L.; Dagorn, J.C.; Lomberk, G.; Urrutia, R.; Goruppi, S.; et al. Nupr1-aurora kinase A pathway provides protection against metabolic stress-mediated autophagic-associated cell death. Clin. Cancer Res. 2012, 18, 5234–5246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Wu, B.; Zeng, W.; Ouyang, W.; Xu, Q.; Chen, J.; Wang, B.; Zhang, X. Quercetin induced NUPR1-dependent autophagic cell death by disturbing reactive oxygen species homeostasis in osteosarcoma cells. J. Clin. Biochem. Nutr. 2020, 67, 137–145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Neag, M.A.; Mocan, A.; Echeverria, J.; Pop, R.M.; Bocsan, C.I.; Crisan, G.; Buzoianu, A.D. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front. Pharmacol. 2018, 9, 557. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  118. Lopes, T.Z.; de Moraes, F.R.; Tedesco, A.C.; Arni, R.K.; Rahal, P.; Calmon, M.F. Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells. Biomed. Pharmacother. 2020, 123, 109794. [Google Scholar] [CrossRef] [PubMed]
  119. Huang, H.; Li, L.; Shi, W.; Liu, H.; Yang, J.; Yuan, X.; Wu, L. The Multifunctional Effects of Nobiletin and Its Metabolites In Vivo and In Vitro. Evid Based Complement. Altern. Med. 2016, 2016, 2918796. [Google Scholar] [CrossRef] [Green Version]
  120. Zhang, R.; Chen, J.; Mao, L.; Guo, Y.; Hao, Y.; Deng, Y.; Han, X.; Li, Q.; Liao, W.; Yuan, M. Nobiletin Triggers Reactive Oxygen Species-Mediated Pyroptosis through Regulating Autophagy in Ovarian Cancer Cells. J. Agric. Food Chem. 2020, 68, 1326–1336. [Google Scholar] [CrossRef]
  121. He, W.T.; Wan, H.; Hu, L.; Chen, P.; Wang, X.; Huang, Z.; Yang, Z.H.; Zhong, C.Q.; Han, J. Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res. 2015, 25, 1285–1298. [Google Scholar] [CrossRef]
  122. Huang, Q.; Lu, G.; Shen, H.M.; Chung, M.C.; Ong, C.N. Anti-cancer properties of anthraquinones from rhubarb. Med. Res. Rev. 2007, 27, 609–630. [Google Scholar] [CrossRef]
  123. Suresh, D.; Srinivasan, K. Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats. Indian J. Med. Res. 2010, 131, 682–691. [Google Scholar]
  124. Chaiyasit, K.; Khovidhunkit, W.; Wittayalertpanya, S. Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J. Med. Assoc. Thail. 2009, 92, 108–113. [Google Scholar]
  125. Sestili, P.; Fimognari, C. Cytotoxic and Antitumor Activity of Sulforaphane: The Role of Reactive Oxygen Species. Biomed. Res. Int. 2015, 2015, 402386. [Google Scholar] [CrossRef] [PubMed]
  126. Clarke, J.D.; Hsu, A.; Yu, Z.; Dashwood, R.H.; Ho, E. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol. Nutr. Food Res. 2011, 55, 999–1009. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  127. Soni, K.; Rizwanullah, M.; Kohli, K. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: In vitro, ex vivo and in vivo assessments. Artif. Cells Nanomed. Biotechnol. 2018, 46, 15–31. [Google Scholar] [CrossRef] [Green Version]
  128. Shi, D.Y.; Liu, H.L.; Stern, J.S.; Yu, P.Z.; Liu, S.L. Alpha-lipoic acid induces apoptosis in hepatoma cells via the PTEN/Akt pathway. FEBS Lett 2008, 582, 1667–1671. [Google Scholar] [CrossRef] [Green Version]
  129. Teichert, J.; Hermann, R.; Ruus, P.; Preiss, R. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J. Clin. Pharmacol. 2003, 43, 1257–1267. [Google Scholar] [CrossRef]
  130. Fofaria, N.M.; Ranjan, A.; Kim, S.H.; Srivastava, S.K. Mechanisms of the Anticancer Effects of Isothiocyanates. Enzymes 2015, 37, 111–137. [Google Scholar] [CrossRef]
  131. Xiao, D.; Vogel, V.; Singh, S.V. Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. Mol. Cancer Ther. 2006, 5, 2931–2945. [Google Scholar] [CrossRef] [Green Version]
  132. Srivastava, S.K.; Singh, S.V. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis 2004, 25, 1701–1709. [Google Scholar] [CrossRef]
  133. Trachootham, D.; Zhou, Y.; Zhang, H.; Demizu, Y.; Chen, Z.; Pelicano, H.; Chiao, P.J.; Achanta, G.; Arlinghaus, R.B.; Liu, J.; et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006, 10, 241–252. [Google Scholar] [CrossRef] [Green Version]
  134. Ji, Y.; Kuo, Y.; Morris, M.E. Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharm. Res. 2005, 22, 1658–1666. [Google Scholar] [CrossRef] [PubMed]
  135. Lin, Y.; Xu, J.; Liao, H.; Li, L.; Pan, L. Piperine induces apoptosis of lung cancer A549 cells via p53-dependent mitochondrial signaling pathway. Tumour Biol. 2014, 35, 3305–3310. [Google Scholar] [CrossRef] [PubMed]
  136. Johnson, T.M.; Yu, Z.X.; Ferrans, V.J.; Lowenstein, R.A.; Finkel, T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 1996, 93, 11848–11852. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  137. Jumpa-ngern, P. Pharmacokinetics of piperine following single dose administration of benjakul formulation in healthy Thai subjects. Afr. J. Pharm. Pharmacol. 2013, 7, 560–566. [Google Scholar] [CrossRef]
  138. Kim, B.; Kim, H.S.; Jung, E.J.; Lee, J.Y.; Tsang, B.K.; Lim, J.M.; Song, Y.S. Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells. Mol. Carcinog. 2016, 55, 918–928. [Google Scholar] [CrossRef]
  139. Dei Cas, M.; Ghidoni, R. Dietary Curcumin: Correlation between Bioavailability and Health Potential. Nutrients 2019, 11, 2147. [Google Scholar] [CrossRef] [Green Version]
  140. Thaiparambil, J.T.; Bender, L.; Ganesh, T.; Kline, E.; Patel, P.; Liu, Y.; Tighiouart, M.; Vertino, P.M.; Harvey, R.D.; Garcia, A.; et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int. J. Cancer 2011, 129, 2744–2755. [Google Scholar] [CrossRef]
  141. Committee for Medicinal Products for Veterinary Use. European Public MRL Assessment Report (EPMAR) Bromelain; European Medicines Agency: Amsterdam, The Netherlands, 2017. [Google Scholar]
  142. Ji, P.Y.; Li, Z.W.; Yang, Q.; Wu, R. Rapid determination of ruscogenin in rat plasma with application to pharmacokinetic study. J. Chromatogr. B 2015, 985, 71–74. [Google Scholar] [CrossRef]
  143. Song, M.; Liu, X.; Liu, K.; Zhao, R.; Huang, H.; Shi, Y.; Zhang, M.; Zhou, S.; Xie, H.; Chen, H.; et al. Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo. Mol. Cancer Ther. 2018, 17, 1540–1553. [Google Scholar] [CrossRef] [Green Version]
  144. Liu, J.; Zhang, N.; Li, N.; Fan, X.; Li, Y. Influence of verapamil on the pharmacokinetics of oridonin in rats. Pharm. Biol. 2019, 57, 787–791. [Google Scholar] [CrossRef] [Green Version]
  145. Gao, Y.; Islam, M.S.; Tian, J.; Lui, V.W.; Xiao, D. Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. Cancer Lett. 2014, 349, 15–25. [Google Scholar] [CrossRef] [PubMed]
  146. Hunsakunachai, N.; Nuengchamnong, N.; Jiratchariyakul, W.; Kummalue, T.; Khemawoot, P. Pharmacokinetics of cucurbitacin B from Trichosanthes cucumerina L. in rats. BMC Complement. Altern. Med. 2019, 19, 157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  147. Hoh, C.; Boocock, D.; Marczylo, T.; Singh, R.; Berry, D.P.; Dennison, A.R.; Hemingway, D.; Miller, A.; West, K.; Euden, S.; et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: Silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin. Cancer Res. 2006, 12, 2944–2950. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  148. Tan, X.S.; Ma, J.Y.; Feng, R.; Ma, C.; Chen, W.J.; Sun, Y.P.; Fu, J.; Huang, M.; He, C.Y.; Shou, J.W.; et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS ONE 2013, 8, e77969. [Google Scholar] [CrossRef]
  149. Chen, J.; Chen, A.Y.; Huang, H.; Ye, X.; Rollyson, W.D.; Perry, H.E.; Brown, K.C.; Rojanasakul, Y.; Rankin, G.O.; Dasgupta, P.; et al. The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway. Int. J. Oncol. 2015, 46, 2629–2638. [Google Scholar] [CrossRef] [Green Version]
  150. Singh, S.P.; Wahajuddin; Tewari, D.; Patel, K.; Jain, G.K. Permeability determination and pharmacokinetic study of nobiletin in rat plasma and brain by validated high-performance liquid chromatography method. Fitoterapia 2011, 82, 1206–1214. [Google Scholar] [CrossRef]
  151. Dumit, V.I.; Zerbes, R.M.; Kaeser-Pebernard, S.; Rackiewicz, M.; Wall, M.T.; Gretzmeier, C.; Kuttner, V.; van der Laan, M.; Braun, R.J.; Dengjel, J. Respiratory status determines the effect of emodin on cell viability. Oncotarget 2017, 8, 37478–37490. [Google Scholar] [CrossRef]
  152. Wu, W.; Yan, R.; Yao, M.; Zhan, Y.; Wang, Y. Pharmacokinetics of anthraquinones in rat plasma after oral administration of a rhubarb extract. Biomed. Chromatogr. 2014, 28, 564–572. [Google Scholar] [CrossRef]
Antioxidants 10 00083 g001 550
Figure 1. Reactive Oxygen Species (ROS)-mediated apoptotic action of phytochemicals. Figure created with BioRender.com.
Figure 1. Reactive Oxygen Species (ROS)-mediated apoptotic action of phytochemicals. Figure created with BioRender.com.
Antioxidants 10 00083 g001
Antioxidants 10 00083 g002 550
Figure 2. ROS-mediated ferroptotic action of phytochemicals. Figure created with BioRender.com.
Figure 2. ROS-mediated ferroptotic action of phytochemicals. Figure created with BioRender.com.
Antioxidants 10 00083 g002
Antioxidants 10 00083 g003 550
Figure 3. ROS-mediated autophagic action of phytochemicals. Figure created with BioRender.com.
Figure 3. ROS-mediated autophagic action of phytochemicals. Figure created with BioRender.com.
Antioxidants 10 00083 g003
Antioxidants 10 00083 g004 550
Figure 4. ROS-mediated pyroptotic action of phytochemicals. Figure created with BioRender.com.
Figure 4. ROS-mediated pyroptotic action of phytochemicals. Figure created with BioRender.com.
Antioxidants 10 00083 g004
Antioxidants 10 00083 g005 550
Figure 5. ROS-mediated anoikis by phytochemicals. Figure created with BioRender.com.
Figure 5. ROS-mediated anoikis by phytochemicals. Figure created with BioRender.com.
Antioxidants 10 00083 g005
Table
Table 1. Phytochemicals are associated with ROS-mediated programmed cell death in cancer.
Table 1. Phytochemicals are associated with ROS-mediated programmed cell death in cancer.
Sr. No.PhytochemicalPCD TypeEffective Anti-Cancer Concentration (In Vitro)Dose Administered (In Vivo)Pharmacokinetic DataTttCell Lines/SubjectsOutcome/CommentsReferences
1CapsaicinApoptosis150 µM2.5 mg/kgNot statedAnimal subject—Mice
In vitro study Pancreatic cancer cells		Apoptosis was observed in AsPC-1 and BXPC3 cell lines at 150 µM concentration, while no effect were observed in normal (HPDE-6) cells. In an animal study, an oral dose 2.5 mg/kg was effective in suppressing tumor growth. Human equivalent dose—0.202 mg/kg.[67,68]
2Capsaicin (Pharmacokinetic study)--5 gCmax: 2.47 ± 0.13 ng/mLHuman subjectsThe oral bioavailability of capsaicin is effective for anti-diabetic effect, but plasma level is less for its anti-cancer activity.[123,124]
3SulforaphaneApoptosis5–10 µM---Various studies report anticancer activity in a range of 5–10 µM which is not attainable through dietary intake. A study in normal vs. cancerous prostate cells revealed selective cytotoxicity of sulforaphane in cancerous cells. No effect was observed in normal cells at a dose range of 0–15 µM.[125,126]
4Sulforaphane (Pharmacokinetic study)--30 mg/kgCmax: 772.8 ± 54.36 ng/mLAnimal subject—RatsNano structured lipid formulation of sulforaphane increased its bioavailability in rat plasma wherein a dose close to effective anticancer level was achieved.[127]
5α-lipoic acidApoptosis500 µM--In vitro study hepatoma cell lineROS-mediated apoptosis was observed at 500 µM. However, in another study, no effect was observed in normal L02 liver cells at 5 mM concentration.[72,128]
6α-lipoic acid (Pharmacokinetic study)--600 mg per dayCmax:
8–52 nM		Human subjectsPlasma levels achieved in plasma following oral administration of racemic α-lipoic acid is much less than required for its anti-cancer activity.[129]
7BITCApoptosis---In vitro study Pancreatic cancer cellsBITC caused ROS generation in a concentration dependent manner starting from 2.5 to 20 µM in MIAPaCa-2 and Capan-2 cell lines[79,130]
8BITCApoptosis<2.5–5 µM--In vitro study Breast cancer cells and normal mammary epithelial cell lineBITC induced ROS-mediated apoptosis in MDA-MB-231 and MCF-7 at IC50 value of <2.5 µm and 5 µM respectively at 24-h time point. However, the IC50 was 20 µM in normal mammary epithelial cell line MCF-10A.[131]
9BITCApoptosis8 µM--In vitro study Pancreatic cancer cellsAn IC50 of 8 µM was observed when BXPC3 cells were treated with BITC.[132]
10BITC (Pharmacokinetic study)--12 µM/dayCmax:
7.5 µM in tumor		Animal subject—MiceBXPC3 cells were subcutaneously implanted and a 43% tumor inhibition was observed with a concentration near IC50 value achieved in plasma.[74]
11PEITCApoptosis<5 µM--In vitro study Breast cancer cellsPEITC caused ROS-mediated apoptosis in MDA-MB-231 and MCF-7 cell lines. [86]
12PEITC Apoptosis5–10 µM--In vitro study normal ovarian epithelial cell lineOvarian epithelial cell line T72 was transfected to over express Ras oncogene to form oncogenic T72Ras cell line. Following PEITC treatment, the transformed cells showed higher sensitivity to ROS as compared to normal cells. Thus, showing selective activity of PEITC. [133]
13PEITC (Pharmacokinetic study)--10–100 µmol/kgCmax:
9–42 µM		Animal subjects—RatsA considerably high level of PEITC was achieved after oral administration of PEITC than required for its anti-cancer activity.[134]
14PiperineApoptosis136–137 µM--In vitro study
Melanoma cell lines		Piperine induced RPS mediated apoptosis in SKMEL-28 and B16-F0 cells at 136 µM and 137 µM respectively at 72-h time point.[90]
15PiperineApoptosis132 µg/mL--In vitro study
Lung cancer cells and normal lung fibroblasts		Piperine induced apoptotic cell death via p53 dependent mitochondrial pathway in A549 cancer cell line while no significant cytotoxicity was observed in normal WI38 human lung fibroblasts. ROS are considered to be downstream effectors of p53 mediated apoptosis.[135,136]
16Piperine (Pharmacokinetic study)--200 mg tablets (Benjakul formulation)Cmax:
1.078 µg/mL		Human subjectsPiperine is a major component of a traditional Thai medication called Benjakul. A dose of 200mg resulted in a Cmax level of 1.078 µg/mL which is significantly lower than that required for anticancer effect.[137]
17CurcuminApoptosis25 µM5 mg/kg-In vitro study
Colorectal cancer cells
Animal subjects—Mice		Curcumin induced ROS-mediated apoptotic cell death in HCT-116 cell line at 25 µM concentration within 48hh.
Curcumin showed considerable tumor inhibition in in vivo xenograft model following administration of 5 mg/kg I.P dose. 		[93]
18CurcuminApoptosis20 µM--In vitro study
Cervical cancer cells and normal cervical cells		Curcumin induced ROS-mediated apoptosis in cervical cancer cell lines C33A, CaSki, HeLa, and ME180 cells at approximately 20 µM in 48-h time period, while it did not induce significant toxicity in normal counterparts until 40 µM concentration.[138]
19Curcumin (Pharmacokinetic study)--Various doses (2–10 g)Cmax: 1–3200 ng/mLHealthy human volunteers and patients (cancer, Alzheimer’s disease etc.)The serum levels of curcumin achieved by oral administration of crude curcumin are much lower than required for anti-cancer activity. However, a 10–15-fold increase in plasma levels was observed when curcumin was formulated as nanoparticle or combined with piperine, lecithin, etc.[139]
20Withaferin AFerroptosis5–10 µM4 mg/kgNot statedIn vitro study
Neuroblastoma cell lines
Animal subjects— Mice		Crude Withaferin A and its nano particle formulation for tumor targeting showed ROS-mediated ferroptosis at 10 µM in neuroblastoma cell lines IMR-32, SK-N-SH, Kelly, NB69, and CHP-134 within 4–8 h. Tumor regression was mediated through lipid peroxidation.[95]
21Withaferin AApoptotic1–50 µM4 mg/kgCmax:
1.8 µM		In vitro study
Breast cancer cell lines
Animal subject—Mice		Withaferin A displayed cytotoxicity in breast carcinoma cell lines MDA-MB 231, H1299, T47D, MCF-7, LN686, as well as normal fibroblast cell line COS-7 in a wide range of 1–50 µM at 72-h time point. The IC50 was lesser than normal fibroblasts in majority of the cancer cell lines.
[140]
22BromelainFerroptosis-3 mg/kgNot statedIn vitro study
Colon carcinoma cell lines and normal colon cell line.
Animal subjects—Mice		Bromelain inhibited proliferation of in Kras mutant colon cancer cell lines HCT-116 and DLD-1 at 50 µg/mL, while it induced significant ferroptosis in cancer cell lines at a concentration of 5 µm when combined with Erastin as compared to normal colon cells CCD1co. Bromelain increased survival rate in treatment group as compared to vehicle group.[81]
23Bromelain (Pharmacokinetic study)--143 mg/kgCmax: Very low (specific value not stated)Human subjectsBromelain showed very low (ng/mL) plasma levels following oral administration at 143 mg/kg body weight.[141]
24RuscogeninFerroptosis7.3–28.19 µM5 or 10 mg/kgNot statedIn vitro study Pancreatic cancer cells
Animal subjects—Mice		Ruscogenin induced significant ferroptotic cell death in pancreatic cancer cell lines BxPC-3, SW1990, PANC-1, and ASPC-1 cells, as compared to normal pancreatic cell line HPDE-6-C7 wherein not IC50 was detected at 72-h time point in HPDE6-C7 cells. Additionally, it inhibited pancreatic cancer growth in vivo.[99]
25Ruscogenin (Pharmacokinetic study)--8 mg/kgCmax:
504.50 ± 63.47 ng/mL (Mean value)		Animal subjects—RatsFollowing IV administration of Ruscogenin in rats, a plasma level between 2–1000 ng/mL was observed which roughly translates to 2.35 µM, a level much lower than required for anticancer effect.[142]
26OridoninFerroptosis26.93 µM--In vitro study
Esophageal cancer cells		Oridonin induced ferroptotic cell death in esophageal cancer cell line TE1 at 27 µM within 24-h time point.[101]
27OridoninApoptosis2.5–10 µM--In vitro study
Esophageal cancer cell lines		Oridonin induced cellular death in human esophageal cancer cell lines (KYSE70, KYSE410, and KYSE450) at 2.5–10 µM concentration, while it showed 40% cell death in normal esophageal cell line SHEE at 40 µM, a significantly higher concentration.
[143]
28Oridonin (Pharmacokinetic study)--20 mg/kgCmax: 146.9 ± 10.17 ng/mLAnimal subjects—RatsA concentration of approximately 150 ng/mL translating to 412 nM was achieved. Combination with verapamil increased the Cmax level of oridonin to 194 ± 10 ng/mL, still a lower level for anti-cancer efficacy.[144]
29Cucurbitacin BAutophagyApproximately 1 µM--In vitro study
Cervical cancer cell line and breast cancer cell lines		Cucurbitacin B induced caspase independent autophagic cell death in HeLa cells at 1 µM. Additionally, it induced autophagy and increased ROS levels in MCF-7 at 200 nM. Autophagic cell death in normal counterparts was not studied.[104]
30Cucurbitacin BApoptosis0.2 µM--In vitro study
Prostate cancer cell lines		Cucurbitacin B induced cell death and ROS production in human prostate cancer cell lines LNCaP and PC-3 at 0.2 µM while no significant cell death or ROS production was observed in normal prostate cell line PrEC.[145]
31Cucurbitacin B (Pharmacokinetic study)--2–4 mg/kgCmax:
9–31 µg/L		Animal subjects—RatsFollowing an oral administration of 2–4 mg/kg, a significantly low plasma level was achieved in rat plasma than required for anti-cancer activity.[146]
32SilibininAutophagy40 µM--In vitro study
Fibrosarcoma cells		Silibinin induced autophagy in human fibrosarcoma cell lines HT1080 at 40 µM within a period of 4 h. Cellular death was concluded to be an autophagy mediated apoptosis process. Effect on normal cells was not studied.[106]
33Silibinin (Pharmacokinetic study)--360, 720 and 1440 mgCmax:
0.4, 1.4 and 4 ± 5.3 µM respectively		Human Subjects—Colorectal cancer patientsSilibinin formulated capsules showed considerably high levels required to exert its anti-tumor effect.[147]
34AllicinAutophagy and apoptosis15–30 µg/mL--In vitro study
Non-small cell lung cancer cell lines		Allicin induced both autophagy and apoptosis in human lung cancer cell lines A549 and NCI-H460.[109]
35CarnosolAutophagy<25 µM--In vitro study
Breast cancer cell lines		Carnosol induced ROS-mediated autophagy in triple negative breast cancer cell line MDA-MB-231. Effect on normal cell counterparts was not studied.[113]
36QuercetinAutophagy200 µM100 mg/kg-In vitro study
Osteosarcoma cell line
Animal subjects—Mice		Quercetin induced ROS-mediated autophagic cell death in human osteosarcoma cell line MG-63 and also inhibited tumor growth in mice model.[116]
37BerberineAutophagy---In vitro study
Renal carcinoma cell lines and normal kidney cell line.		Berberine induced autophagic cell death in 786-O, ACHN cell lines via its photosensitizer activity when combined with laser.
Additionally, it induced cell death in normal kidney cell line HK-2 at when combined with laser. Treatment with Berberine alone failed to induce cell death >20% in cancer cells, while it induced cell death >20% in HK-2 normal cells at 40 µM within 48 h.		[118]
38Berberine (Pharmacokinetic study)--200 mg/kgCmax:
25.85 ± 7.34 µg/L		Animal subject— RatsA plasma level of 25.85 ± 7.34 µg/L equivalent to 76 µM was achieved.[148]
39NobiletinPyroptosis34.85–35.31 µM--In vitro study
Ovarian cancer cell lines		Nobiletin induced cytotoxicity at concentration of 35 µM but no data regarding its effect on normal cell lines were shown.[120]
40NobiletinApoptosis40–80 µM100 mg/kg-In vitro study
Ovarian cancer cell lines OVCAR-3 and A2780
Animal subject— Mice		Nobiletin exhibited cytotoxicity in ovarian cancer cell lines at 40–80 µM while the IC50 for normal ovarian cell line was around 160 µM.
Additionally, significant tumor growth inhibition was observed in athymic nude mice model at a dose of 100 mg/kg.		[149]
41Nobiletin (Pharmacokinetic study)--50 mg/kgCmax:
1.78 µg/mL in plasma		Animal subject—RatsThe plasma level achieved after oral administration is 1.78 µg/mL which correlates to approximately 4–5 µM.[150]
42EmodinAnoikis10 µM--In vitro study
Gastric cancer cell lines		Significant difference observed in RhoA expression between cancer and normal cell lines.[61]
43EmodinApoptosis70 µM--In vitro study
Cancer cell lines isolated from breast, lung, colon, and cervix carcinomas, normal human fibroblasts, and normal human keratinocytes		No effect observed on normal cell lines after 48-h treatment while cytotoxicity was observed in cancer cell lines.[151]
44Emodin (Pharmacokinetic study)--4.5 mg/kgCmax: 0.2 ± 0.1 µMAnimal subject—RatsThe concentration of free emodin achieved in rat plasma after oral administration of rhubarb extract was found to be much lower than required for its anti-cancer activity.[152]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Gaikwad, S.; Srivastava, S.K. Role of Phytochemicals in Perturbation of Redox Homeostasis in Cancer. Antioxidants 2021, 10, 83. https://doi.org/10.3390/antiox10010083

AMA Style

Gaikwad S, Srivastava SK. Role of Phytochemicals in Perturbation of Redox Homeostasis in Cancer. Antioxidants. 2021; 10(1):83. https://doi.org/10.3390/antiox10010083

Chicago/Turabian Style

Gaikwad, Shreyas, and Sanjay K. Srivastava. 2021. "Role of Phytochemicals in Perturbation of Redox Homeostasis in Cancer" Antioxidants 10, no. 1: 83. https://doi.org/10.3390/antiox10010083

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop